Pharmacoemissions: contribution of an ageing population to emissions arising from utilisation of pharmaceutical products

Show simple item record

dc.contributor.advisor Chapman, Deborah en
dc.contributor.author Bacci, Fabio
dc.date.accessioned 2017-03-23T09:45:30Z
dc.date.issued 2016
dc.date.submitted 2016
dc.identifier.citation Bacci, F. 2016. Pharmacoemissions: contribution of an ageing population to emissions arising from utilisation of pharmaceutical products. PhD Thesis, University College Cork. en
dc.identifier.uri http://hdl.handle.net/10468/3824
dc.description.abstract Emissions of pharmaceuticals into the environment are growing proportionately to the level of consumption of medicinal products. Likewise, the general upward trends in consumption of pharmaceuticals across the European Union (EU) are influenced by epidemiological changes, demographic changes and lifestyle expectations experienced in many Member States. Research on pharmaceuticals in the environment is expanding at a significant rate, elucidating more aspects of this emerging environmental issue. Despite that, the knowledge base on pharmaceuticals in the environment is still markedly limited, primarily because of challenges posed by the sheer number of substances available on the market, exceeding 3,000 pharmaceutical ingredients worldwide. This research focused on explaining two aspects of the emission of pharmaceuticals into the environment. The principal investigation of the research consisted of addressing the novel question of the contribution to the emissions levels exerted by one aspect of demographic change: population ageing. This multidisciplinary research question framed the overall scope of the study, leading to the investigation of consumption of medicinal products. Availing of a five and half year prescribing data sample for Ireland covering the period from 2008 to 2013, the study progressed into the statistical analysis of consumption patterns, which evolved into a systematic methodology, developed in R statistical software, for the rapid assessment of historical and forecast trends of consumption of medicinal products. In addition to assisting in measuring the contribution of population ageing to the consumption of pharmaceutical products in Ireland, the software developed in R also provided empirical evidence on trends of consumption, potentially warranting research of substances currently belonging to the knowledge gaps on the occurrence of pharmaceuticals in the environment. For instance the antineoplastic mercaptopurine was identified because, along with the intrinsic toxicity of the substance, outpatient consumption increased by 13.2 % per annum during the data sample period. The research showed that, while population ageing caused an increase in contribution to the consumption of 66.7 % of the substances assessed (n = 84), a general increase in consumption, irrespective of demographic changes, was measured for 77.5 % of the formulary of pharmaceutical products evaluated (n = 89). A six month survey measuring environmental concentrations in the treated effluent of a major urban sewage treatment plant of the antiepileptic pregabalin, one of the substances showing the highest annual change in consumption (28.5 %), was conducted to validate the statistical analyses of consumption patterns. Pregabalin was detected in 100 % of the samples analysed (n = 10) at an average monthly concentration of 1.11 ± 0.22 μg/L. The modelling conducted in this research demonstrated the erratic pattern of consumption for most pharmaceutical substances suggesting that measured environmental concentrations of pharmaceutical products reported in the body of literature are likely to be transient. Since October 2005 holders of patents of new molecules seeking to enter the EU market have had to provide an environmental risk assessment before the medicinal product could be marketed. In light of the erratic consumption trends identified by this research, the long-term validity of such environmental risk assessments may be disputed. en
dc.description.sponsorship Irish Research Council (Embark Initiative RS/2012/264) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher University College Cork en
dc.rights © 2016, Fabio Bacci. en
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/ en
dc.subject Pharmaceuticals in the environment en
dc.subject Pharmacoemissions en
dc.subject Population ageing en
dc.subject Demographic change en
dc.subject Environmental risk assessment en
dc.subject Emission forecast en
dc.subject Pregabalin en
dc.subject Solid phase extraction en
dc.title Pharmacoemissions: contribution of an ageing population to emissions arising from utilisation of pharmaceutical products en
dc.type Doctoral thesis en
dc.type.qualificationlevel Doctoral en
dc.type.qualificationname PhD (Science) en
dc.internal.availability Full text not available en
dc.check.info Indefinite en
dc.check.date 10000-01-01
dc.description.version Accepted Version
dc.contributor.funder Irish Research Council en
dc.description.status Not peer reviewed en
dc.internal.school Biological, Earth & Environmental Sciences en
dc.check.type No Embargo Required
dc.check.reason This thesis is due for publication or the author is actively seeking to publish this material en
dc.check.opt-out Yes en
dc.thesis.opt-out true
dc.check.embargoformat Hard bound copy in Library only en
dc.internal.conferring Spring 2017 en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

© 2016, Fabio Bacci. Except where otherwise noted, this item's license is described as © 2016, Fabio Bacci.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement